Table 4.
Specificity results with the negative samples (N = 200).
| HST/HT | EXACTO PRO TEST HIV | EZ-TRUST HIV 1 & 2 rapid screen Test | Genie fast HIV1/2 | HIVTOP |
INSTI | STAT-VIEW HIV 1/2 | VIKIA HIV 1/2 | BioTechMed HIV1/2 Rapid-4 a |
HIV combo |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T2 | T1 | T2 | Ag | Ac | |||||||
| Nbr of positive samples | 3 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Specificity | 98,50% | 100% | 100% | 99% | 100% | 100% | 100% | 99,50% | 100% | 100% | 99,50% | 100% |
| 95% CI (%) | 95·3–99·6 | 97·6–100 | 97·6–100 | 96·0–99·8 | 97·6–100 | 97·6–100 | 97·6–100 | 96·8–99·9 | 85·9–100 | 85·9–100 | 96·8–99·9 | 97·6–100 |
Specificity was evaluated on 200 HIV-negative whole blood samples with seven 3G RSTs/STs (left part of the table) and two 4G RSTs/STs (right part of the table). The table reports the false-positive results. For the HIV Combo (Alere) test, the detection of p24Ag is performed with a specific line, distinct from the antibody line. No antigen-specific line was present in the BioTechMed HIV1/2 Rapid-4 test. HIVTOP and BioTechMed HIV1/2 Rapid-4 are designed to discriminate HIV-1 from HIV-2 infections; results for both HIV-1 and HIV-2 are reported.
a
N = 30 samples.